Cytogenetics Update Lynda J Campbell lynda.campbell@svhm.org.au Ph - - PowerPoint PPT Presentation

Cytogenetics Update

Lynda J Campbell lynda.campbell@svhm.org.au

Ph

Nowell and Hungerford, 1960

9 22

Janet Rowley showed the Ph chromosome to be a balanced rearrangement: t(9;22)

Acute lymphoblastic leukaemia

EFS of patients treated on UK MRC ALL97 by cytogenetic subgroup

Moorman et al, Blood, 2007

t (12;21)(p13;q22)

• 4 year old boy presented

with sudden onset of tiredness and bruising

• FBE showed blasts in PB

46,XY,del(12)(p13)[22]

HEH karyogram

High hyperdiploidy in paediatric ALL

• Hyperdiploidy in acute lymphoblastic leukaemia associated with

consistent pattern of trisomies and often four copies of chromosome 21

• FISH for trisomies of 4, 10 and 17

ETV6/RUNX1 CEP4, 10, 17

t(4;11)(q21;q23)

• t(4;11) seen in
• approx. 3-5%

childhood and adult ALL - immature phenotype and

• ften myeloid

antigen

• High white cell

count

• poor prognosis

in both children and adults

Ph+ ALL

• 15-30% adult ALL but
• nly about 3%

childhood ALL

• either p190 or p210

fusion product seen

• associated with a

dismal prognosis in both adults and children

• transplant candidates
• Some promising

results with imatinib therapy

t(17;19)(q22;p13) with TCF3-HLF fusion

• t(17;19)(q22;p13) gives rise to the TCF3-HLF fusion
• It is a variant of t(1;19)(q23;p13), TCF3-PBX1 fusion.
• Very rare
• Extremely poor outcome in paediatric series
• Usually visible by cytogenetic analysis but may be

confirmed using the dual colour breakapart probe specific for TCF3 (E2A)

• Report of t(17;19) in 23 adults showed no difference in
• verall survival compared with negative patients

(Burmeister et al, Haematologica, 2010)

Multiple copies of RUNX1 clustered on a marker chromosome

intrachromosomal amplification of chromosome 21 (iAMP21)

• 2% childhood ALL - pre-B immunophenotype,
• significantly older (median 9 years vs 5 years),
• lower white cell count (median 3.9 vs 12.4)
• significantly inferior EFS at 5 years : 29% versus 78%

and overall survival 71% versus 87% respectively.

• 3-fold increase in relapse risk,
• New patients with iAMP21 on UK MRC ALL2003 trial

 high-risk arm and considered for bone marrow transplantation in first CR.

Adult ALL

• Philadelphia status generally considered the most

important cytogenetic indicator of outcome

• MRC/ECOG collaborative study of >1500 adults with

ALL identified:

Inferior outcome Improved outcome Ph translocation High hyperdiploidy t(4;11)(q21;q23) Deletion of 9p Burkitt translocation* Complex karyotype (≥ 5) * Low hypodiploidy/triploidy * Moorman et al, Blood 2007

* Independent of sex, age, WCC and T-cell

WHO 2008 classification of AML: AML with recurrent genetic abnormalities

• AML with t(8;21); RUNX1-RUNX1T1
• AML with inv(16) or t(16;16); CBFB-MYH11
• APL with t(15;17); PML-RARA*
• AML with t(9;11); MLLT3-MLL#
• AML with t(6;9); DEK-NUP214
• AML with inv(3); RPN1-EVI1
• AML (megakaryoblastic) with t(1;22); RBM15-MKL1

Acute Myeloid Leukaemia with t(8;21); RUNX1- RUNX1T1

Cytogenetically Normal AML (CN-AML)

Figure 1. Pie chart illustrating the molecular heterogeneity

• f cytogenetically normal

AML based on mutations in the NPM1, CEBPA, MLL, FLT3 (ITD and TKD mutations at codons D835 and I836), NRAS, and WT1 genes. Data are derived from mutational analysis of 485 younger adult patients with cytogenetically normal AML from AMLSG. Dohner et al, Blood, 115: 453-474, 2010

Acute Promyelocytic Leukaemia

t(15;17)(q22;q21)

PML/RARA fusion

Rare variants:

t(11;17)(q23;q21) – RARA/PLZF t(5;17)(q35;q21) – RARA/NPM t(11;17)(q13;q21) – RARA/NuMA interstitial del(17q) – RARA/STAT5b

PML/RARA probe RARA with PRKAR1A BAC probe

PRKAR1A-RARA fusion in variant APL, Catalano et al, Blood 2007

Inversion 16

AML M4Eo Fusion of CBFB on 16q22 and MYH11 gene on 16p13

AML with maturation with Auer rods & eosinophilia. Fuses the RUNX1 gene on 21 with the RUNX1T1 (CBFA2T1, ETO) gene on 8q22

Probe for inversion 16: CBFB/MYH11 dual fusion translocation probe (Cytocell Aquarius Probe)

MLL break apart probe (Vysis) to confirm t(9;11)

11q23 abnormalities

• Rearrangements of MLL observed in high-risk

paediatric, adult and therapy-related acute leukaemias

• At least 104 different MLL rearrangements

reported with 64 of the translocation partner genes

Commonest MLL rearrangements

MLL partner genes MLL translocation Acute leukaemia AFF1/AF4 t(4;11)(q12;q23) 319/321 ALL MLLT3/AF9 t(9;11)(p22;q23) 41/125 ALL (mostly paed. 84/125 AML MLLT1/ENL t(11;19)(q23;p13.3) 72/87 ALL MLLT10/AF10 ins(10;11)(p12;q23) 40/54 AML MLLT4/AF6 t(6;11)(q27;q23) 28/35 AML ELL t(11;19)(q23;p13.1) 30/31 AML EPS15/AF1P t(1;11)(p32;q23) 7/13 ALL MLLT6/AF17 t(11;17)(q23;q21) 8/8 AML MLLT11 t(1;11)(q21;q23) 7/8 AML (all paediatric) SEPT6 ins(X;11)(q24;q23) 7/7 AML Meyer et al, Leukemia 2009

Overall survival curve for patients with 11q23/MLL- rearranged pediatric AML grouped on the basis of different translocation partners

t(1;11) t(10;11) Balgobind et al, Blood 2009, Vol. 114, No. 12, pp. 2489-2496

10 p13 (AF10) 11 q14 (CALM) q23 (MLL)

Recent case: 23 year man presented with AML

FISH required to diagnose t(10;11)

• Type of rearrangement and breakpoints are

variable.

• Observed in both ALL and AML
• A significant proportion result in an MLL-AF10

fusion (strongly associated with M5/M5a).

• Two other possible transcripts also described.

– CALM-AF10 (seen in both T-ALL and immature AML) – Rarely MLL-ABI-1 (two cases reported)

Van Limbergen et al (2002) proposed 4 recombination patterns for the MLL/AF10:

• Type 1: inversion of MLL then t with 10p13.
• Type 2: inversion of MLL then ins into 10p13.
• Type 3: inversion of AF10 then t with 11q23.
• Type 4: inversion of AF10 then ins into 11q23.
• Morphologically, our case appeared to be a type 2 inversion /

insertion but…

MLL break apart probe: normal result → assumed to be CALM-AF10 fusion formed by translocation

MRC % SWOG/ECOG % Good Inv(16)/t(16;16) ; t(15;17), t(8;21) +/-

• ther abn;

21 % Inv(16)/t(16;16) ; t(15;17)+/- other abn; t(8;21) without del(9q)

• r Cx

20% Intermediate Normal, 11q23 abn, +8, del(9q), del(7q), +21, +22, all others 62 % Normal, +8, +6, -Y, del(12p) 46% Poor Del(5q)/-5, -7, abn 3q, and Complex (≥5 unrelated abn) t(6;9)*, t(9;22)* 17 % Del(5q)/-5, -7/del(7q), abn 3q, 9q, 11q, 20q, 21q, 17p, t(6;9), t(9;22) and Complex (≥3 unrelated abn) 30% Unknown N/A All other abn 4%

Prognosis categories in AML

Ref: Slovak et al, Blood, 96: 4075, 2000; Grimwade et al, Blood, 92: 2322, 1998

Standardized reporting for correlation of cytogenetic and molecular genetic data in AML with clinical data Favourable Intermediate-I Intermediate-II Adverse

t(8;21)(q22;q22); RUNX1-RUNX1T1 Inv(16) or t(16;16) CBFB-MYH11 Normal karyotype: Mutated NPM1 (no FLT3) Mutated CEBPA Normal Karyotype: Mutated NPM1+ FLT3 ITD Wild type NPM1+ FLT3 ITD Wildtype NPM1 + no FLT3 ITD t(9;11)(p22;q23); MLLt3-MLL Cytogenetic abnormalities not classified as favourable or adverse Inv(3q) or t(3;3); RPN1-EVI1 t(6;9)(p23;q34); DEK-NUP214 t(v;11)(v;q23); MLL

• 5 or del(5q)
• 7

Abnormality of 17p Complex karyotype: ≥3 abnormalities

Döhner et al: Recommendations on behalf of the European LeukemiaNet, Blood 2010

Acquired uniparental disomy in CN-AML

Bollinger et al, Leukemia (2010) 24, 438–449

FISH protocol for AML:

• FISH for t(15;17), inversion 16, t(8;21) or an

MLL translocation if morphological or cytogenetic evidence to suggest the presence

• f a either a standard or variant aberration
• FISH for inversion 16 in all follow-up cases

IPSS for MDS: Survival and AML evolution

Score Value Prognostic variable 0.5 1.0 1.5 2.0 BM blasts (%) <5 5-10

• 11-20

21-30 Karyotype# Good Intermediate Poor Cytopenias* 0/1 2/3

#

Good: normal, -Y, del(5q), del(20q) Poor: complex (3) or chromosome 7 abn. Intermediate:

• ther abnormalities

Ref: Greenberg et al, Blood 89: 2079-2088, 1997

*

Cytopenias: Hb <100g/L, Neutrophils <1.8x109/L, Platelets <100x109/L

WPSS for MDS

Variable 1 2 3 WHO category RA, RARS, 5q- RCMD, RCMD- RS RAEB-1 RAEB-2 Karyotype Good Intermediate Poor − Transfusion requirement * No Regular − − Risk groups: Very low score = 0 Low score = 1 Intermediate score = 2 High score = 3-4 Very high score = 5-6 * Transfusion dependency = at least one RBC transfusion every 8 weeks over 4 months Ref: Malcovati et al, JCO, 25: 3503, 2007

Detlef Haase: Updated risk features in MDS

Prog. group Chromosome abnormalities Time to 25% AML Survival (months) Fav. 5q-, 12p-, 20q-, +21, -Y, 11q-, t(11q23), normal, 5q- plus one other abn 71.9 51 Inter1 +1q, 3q21/q26 abn, +8, t(7q), +19, -21, any other single* or double abn 16 29 Inter2

• X, -7/7q-, -7/7q- plus one
• ther abn, complex = 3

abn 6 15.6 Unfav. Complex > 3 abn 2.8 5.9

* Most common group – ie rare abnormalities

FIP1L1

LNX RPL21 CHIC2 MORF4 GSH2

PDGFRA

KIT KDR

cen tel

Deleted region (800 kb)

4q12 region

Ref: Cools et al, NEJM, 2003

RPCI11-120K16 RCPI11-3H20 RCPI11-24O10

Normal metaphase

Abnormal metaphase

Myeloma cytogenetics

• Chromosome abnormalities detected by both

conventional cytogenetics and by fluorescence in situ hybridization (FISH) have been associated with prognosis in multiple myeloma

• Conventional cytogenetic analysis relies on obtaining

dividing cells in culture and analysing the chromosome abnormalities

• Use of FISH allows abnormalities to be detected even

in non-dividing cells

Common cytogenetic abnormalities

• Deletion of 13q observed in 20% by CC and 50% by FISH
• An IGH translocation at 14q32 with an oncogene observed in

 50% patients with myeloma.

• Translocations resulting in dys-regulation of oncogene –

thought to be primary oncogenic events.

IGH partner gene Chromosomal location Incidence Prognostic significance Cyclin D1 11q13 15%

• Cyclin D2

12p13 <1%

• Cyclin D3

6p21 2%

• MAF

16q23 5% Poor MAFB 20q12 2%

• MAFA

8q24.3 <1%

• MMSET/FGFR3

4p16 15% Poor

Myeloma & FISH

• FISH analysis does not distinguish between the

abnormal plasma cell population and other nucleated cells in the bone marrow

• The European Myeloma Network recommendations

for FISH in myeloma 2007 state that “it is not acceptable to report FISH results in myeloma without either concentrating the plasma cells or employing some means of plasma cell identification so that only these cells are scored” .

Identifying Labelled Plasma Cells

• cIg labelling:
• Classic PC

morphology

• Antibody labelling

within cytoplasm

• Easily

distinguishable from other cells

Myeloma cytogenetic/FISH testing

• Conventional cytogenetic analysis: poor

prognosis abnormalities: Hypodiploidy loss of 13q

• FISH:

t(4;14) t(14;16) Deletion of 17p (TP53)

FISH in CLL

Cytogenetic abnormality

• No. cases (325)

Median Survival (months) Deletion 13q 55% 133 Deletion 11q 18% 79 Trisomy 12q 16% 114 Deletion 17p* 7% 32 Normal Karyotype 18% 111

* Independent prognostic indicator (Dohner et al; Krober et al; Oscier et al 2002)

Monoallelic vs biallelic del(13q)

• Loss of one 13q14 (D13S319) signal is the

commonest genetic abnormality in CLL

• As a sole aberration, it predicts a relatively

indolent course

• However, it is not uncommon to find a clone

with loss of both 13q14 alleles

• Does this carry the same prognostic

significance as loss of only one allele?

Chena et al, European J Haematology 2008:

• Studied 103 CLL patients with FISH panels to

detect trisomy12, deletions of ATM (11q22), 13q14 and 13q34 (D13S319 and LAMP1) and TP53 (17p13)

• 6/103 (6%) showed biallelic 13q14 loss as sole

abnormality and 32/103 (31%) with monoallelic loss

• 6/6 vs 12/32 showed disease progression
• Treatment free survival was 28.5 months vs 49

months

Is it CLL or Mantle cell lymphoma?

11 14 t(11;14) Cyclin D1

MCL characterised by t(11;14)(q13;q32)

• Causes cyclin D1 upregulation (BCL1, PRAD1, CCND1)

FISH probe: IGH/CCND1 dual colour dual fusion translocation probe

“double hit” lymphomas

• Rare neoplasms characterised by highly

aggressive clinical behaviour, complex karyotypes and pathological features overlapping BL, DLBCL and B-lymphoblastic lymphoma/leukaemia

• May have history of FL
• 93 cases over 3 studies: 48 B-cell lymphomas

unclassifiable, 45 DLBCL*, 1 B-LBL, 1 FL

• commonly: stage 3-4 disease; high LDH levels;

extra nodal disease; BM involvement; CNS disease

Niitsu et al, Leukemia 2009 Snuderl et al, Am J Surg Pathol 2010 Johnson et al, 2009

MYC break apart probe Dual fusion IGH/BCL2 probe

“Double – hit” lymphoma

• More commonly t(8;22) rather than t(8;14) or

non-Ig / MYC translocations plus higher number of chromosomal aberrations

• At 5 years, only 6 survivors and 32 died within

6 months of MYC translocation (Johnson et al)

• Median overall survival 4.5 months inferior to

both BL and IPI matched DLBCL (Snuderl et al)

Niitsu et al, Leukemia 2009 Snuderl et al, Am J Surg Pathol 2010 Johnson et al, 2009

Dual translocations in DLBCL

Niitsu et al, Leukemia 2009

Acknowledgements: Staff of the VCCS

Cris Batzios Karen Binnion Rebecca Bowen Melissa Curtis Pina D’Achille Caroline Dobrzelak Lee Harrison Veronica Hoctor Kinjal Joshi Ruth MacKinnon Bruce Mercer Trish Michael Megan Nolan Srilakshmi Nutalapati Fran O’Malley Sarah Poile Kathleen Rayeroux Anne Robertson Dora Stamatonikolos Lan Ta Meg Wall Joanne White Adrian Zordan